6533b860fe1ef96bd12c3b0e

RESEARCH PRODUCT

Does tamoxifen change oestrogen and progesterone receptor expression in the endometrium and breast?

U KarckFriedrich Kommoss

subject

Cancer Researchmedicine.medical_specialtyAntineoplastic Agents Hormonalmedicine.drug_classMammary glandBreast NeoplasmsEndometriumEndometriumBreast cancerInternal medicineProgesterone receptormedicineHumansBreastskin and connective tissue diseasesbusiness.industryAntiestrogenmedicine.diseaseEndometrial NeoplasmsTamoxifenmedicine.anatomical_structureEndocrinologyOncologyReceptors EstrogenEstrogenImmunohistochemistryFemalebusinessReceptors Progesteronehormones hormone substitutes and hormone antagonistsTamoxifenmedicine.drug

description

We studied the expression of oestrogen and progesterone receptors (ER, PR) in postmenopausal women receiving tamoxifen for breast cancer. In addition the literature addressing the question of ER and PR expression in breast tissue during treatment with tamoxifen was reviewed. We demonstrated consistent expression of ER and PR in endometria from patients receiving tamoxifen, with a trend towards a higher proportion of receptor positive specimens during tamoxifen. In breast cancer tissue, the ER content seemed to be reduced following tamoxifen treatment. After short time exposure to tamoxifen, the PR appeared to be increased, longer treatment caused the PR to go down to pretreatment levels or below.

yearjournalcountryeditionlanguage
2000-11-01European journal of cancer (Oxford, England : 1990)
10.1016/s0959-8049(00)00222-7https://pubmed.ncbi.nlm.nih.gov/11056315